Noga Ron-Harel, PhD

Aged cancer patients are less tolerant to the detrimental side effects of classical therapies, especially immunotherapy, as the immune response may weaken with age. Dr. Ron-Harel is investigating cellular and systemic effects of aging on immunotherapy, looking at T cells’ central role in the immune defense against cancer. Her team hopes to identify metabolic barriers impairing T-cell therapy in the aged, which could lead to the development of novel treatments that improve therapeutic outcomes by enhancing the metabolic fitness of aged T cells.

View Grant Recipient Profile